Monte Carlo calculation of radioimmunotherapy with ^90Y-, ^177Lu-, ^131I-, ^124I-, and ^188Re-nanoobjects: choice of the best radionuclide for solid tumour treatment by using TCP and NTCP concepts

DOI10.1155/2015/284360MaRDI QIDQ308774zbMATH OpenOpenAlexDBLPWikidataFDO

Authors S. Lucas, O. Feron, B. Gallez, B. Masereel, C. Michiels, T. Vander Borght

Publication date 6 September 2016

Published in Computational \& Mathematical Methods in Medicine (Search for Journal in Brave)

Copyright license Creative Commons Attribution 3.0 Unported

Full work available at URL https://doi.org/10.1155/2015/284360

zbMATH Keywords

monoclonal antibodiesnanoobjectsradioimmunotherapyradioisotopes

Mathematics Subject Classification ID

Monte Carlo methods (65C05) Medical applications (general) (92C50)

Review text

Summary: Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like \(^{131}\)I or \(^{90}\)Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of \(^{90}\)Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as \(^{90}\)Y, \(^{177}\)Lu, \(^{131}\)I, \(^{124}\)I, and \(^{188}\)Re are used. Tumour control probability (TCP) and normal tissue complication probability (NTCP) curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody) distributed uniformly or nonuniformly throughout a solid tumour (e.g., non-small- cell-lung cancer (NSCLC)). \(^{90}\)Y and \(^{188}\)Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases.

Recommendations

• Are more complicated tumour control probability models better?
• Immune system - tumour efficiency ratio as a new oncological index for radiotherapy treatment optimization
• Monte Carlo techniques in radiation therapy
• Multinomial model-based formulations of TCP and NTCP for radiotherapy treatment planning
• Linear quadratic and tumour control probability modelling in external beam radiotherapy

This page was built for publication: Monte Carlo calculation of radioimmunotherapy with \(^{90}\)Y-, \(^{177}\)Lu-, \(^{131}\)I-, \(^{124}\)I-, and \(^{188}\)Re-nanoobjects: choice of the best radionuclide for solid tumour treatment by using TCP and NTCP concepts

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q308774)